Combined plasminogen deficiency and resistance to activated protein C defect (factor V Leiden) have been described in a few families and associated with a variable occurrence of thrombotic events. Here we describe a new family with thrombophilia and the presence of hypoplasminogenemia and factor V Leiden mutation. In addition, a brief review of the literature is presented. Nine patients belonging to this kindred underwent coagulation study for hereditary thrombophilia, which included plasminogen antigen and activity assays, an activated protein C resistance test, and genetic analysis for factor V Leiden mutation and for prothrombin variant 20210A. The proposita, a 40-year-old asymptomatic female with a family history of thrombotic diathesis, was affected by heterozygous plasminogen deficiency. Hypoplasminogenemia was found also in her two sisters, in one instance associated with factor V Leiden mutation. The mother was the putative carrier of hypoplasminogenemia, but she refused to be studied. The symptomatic father was heterozygous for factor V Leiden mutation, but presented with normal plasminogen levels. Among the available siblings investigated from the paternal side, resistance to activated protein C due to factor V Leiden mutation was found in three patients, one of whom experienced venous thromboembolism. Another uncle with a history of thrombotic disease showed no coagulation abnormalities. These findings together with the data from literature confirm the role of factor V Leiden as an independent risk factor for venous thromboembolism, whereas isolated hypoplasminogenemia does not seem to increase the risk for thrombosis. There is no clear evidence that the coinheritance of these two defects may be associated with an additional risk for thrombosis compared with the presence of factor V Leiden mutation alone. Key Words: Plasminogen deficiency&mdash;Factor V Leiden mutation&mdash;Inherited throm-bophilia&mdash;Thrombosis.
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Plasminogen is the circulating zymogen of plasmin, which represents the key enzyme of the fibrinolytic system responsible for fibrin clot dissolution. Congenital defects of plasminogen may be characterized by a decreased protein synthesis and/or production of a dysfunctional molecule (1). These defects have been described in patients with thrombotic disease, where an insufficient plasmin-mediated lysis of the thrombus has been suggested as the pathogenetic mechanism of thrombosis (2-10). However, there is no clear evidence of an association between plasminogen defects and risk for thrombosis (11) (12) (13) . The prevalence of thrombosis in patients with plasminogen deficiency is about 25%, and therefore it is lower than the 50% prevalence observed in patients with clotting inhibitors defects (14) . Moreover, the frequency of plasminogen defect cases in cohorts with thromboembolic disease was not significantly different from that observed in the normal population (13) .
Resistance to activated protein C (APC resistance) is a recently discovered mechanism responsible for thrombophilia. Up to 80% of patients with APC resistance phenotype present with a single point mutation in the factor V gene (1691 G~A in exon 10) leading to a substitution of Arg506 by GIn in the factor V molecule (factor V Leiden) (15) (16) . The prevalence of the factor V Leiden mutation in the Caucasian population has been estimated to be up to 6%. In thrombotic cohorts, depending on selection criteria, it ranges between 20% and 50%. The relative risk for thrombosis in heterozygous and homozygous carriers is about 7 and 100, respectively (17) (18) (19) (20) .
A coexistence of factor V Leiden defect has been described in patients with antithrombin, protein C, and protein S deficiency. A more severe thrombotic tendency has been found in patients with clotting inhibitor deficiencies associated with factor V Leiden mutation (21-24).
An association between plasminogen defects and protein C or protein S defects has been reported (25, 26) . Moreover, four unrelated kindreds with combined hypoplasminogenemia and factor V Leiden recently have been described (27-29). The coinheritance of the defects was clinically silent in the first family (27), but was associated with thrombotic events in the other three kindreds (28,29). Züger et al. (28) considered the factor V Leiden mutation as the major hereditary risk factor, and Castaman et al. (29) suggested that the combination of plasminogen deficiency and heterozygous factor V Leiden mutation may not represent a stronger risk factor for venous thromboembolism (VTE) than the presence of each defect alone.
Here we describe a new kindred with combined hypoplasminogenemia and factor V Leiden mutation and variable degrees of thrombotic manifestations.
CASE REPORT
The proposita is a 40-year-old female, who first came to us in 1996 for investigation of inherited thrombophilia. She had never experienced thrombotic events, but her family history was positive for thrombotic diathesis.
Eight other available family members were studied. The older sister of the proband (II-2), aged 43 years, had two consecutive spontaneous abortions at the age of 29 and 33 years, respectively, both with histologic evidence of vessels thromboses and infarctions of the placenta. A 31-year-old sister (II-3) had a spontaneous phlebitis of the right saphena vein at the age of 26 years. The father of the proband, a 69-year-old male, had a history of spontaneous deep vein thrombosis (DVT) of the left leg at age 62 and two superficial phlebitis of the right lower limb. The 63-year-old mother of the proband was asymptomatic and refused to be studied. Five other siblings from the paternal side were investigated. A 75-year-old uncle (1-2) suffered from repeated DVT of the lower limbs and a subclavian vein thrombosis complicated by pulmonary embolism during the last 30 years. Another uncle aged 61 years (1-3) had a history of a spontaneous DVT. A 63-year-old aunt (1-4) and her two daughters (II-4, II-5) were asymptomatic. The family pedigree is shown in Figure 1 .
MATERIALS AND METHODS
Blood samples were drawn between 8:00 AM and 10:00 AM after an overnight fast. Informed consent was obtained from each subject before inclusion in the study. No patient was taking drugs affecting clotting and fibri- nolytic tests at the time of the study. Whole blood (18 mL) was drawn from an antecubital vein and mixed in a plastic syringe containing 2 mL of NaCitrate 0.13 M as an anticoagulant. After centrifugation for 15 minutes at 3,000 xg, aliquots of separated platelet-poor plasma and buffy coat were stored at -30 °C and tested within 1 month.
The following tests were carried out: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, antithrombin activity, protein C and protein S both activity and concentration, antiphospholipids antibodies (APLA), lupus anticoagulant (LA), APC sensitivity ratio (APC-SR), plasminogen activity (PLG:act) and antigen (PLG:Ag), and genetic analysis for factor V Leiden mutation and for prothrombin variant 20210A.
PT, aPTT, and fibrinogen were performed by standard procedures. Protein C, protein S, and antithrombin activity levels were determined by chromogenic methods using commercially available kits (Berichrom PC, Behring, Scoppito, AQ, Italy; IL Protein S test, IL, Milan, Italy; Antithrombin III, Boehringer Mannheim, Germany; respectively) (30). Protein C and protein S antigens were assayed by ELISA methods as previously described (30). The presence of APLA was tested for using Asserachrom APA (Boehringer Mannheim, Germany) as reported (31 ) . LA was assayed using commercially available kits for screening procedures (PTT-LA kit, Stago-Boehringer Mannheim, Milan, Italy, and Lupo-test, Gradipore LTD, Pyrmont, Australia) as previously described (32).
APC-SR was performed on an ACL 3000 Plus (IL, Milan, Italy) with the original aPTT method as previously described (33) . Genomic DNA was extracted from blood by standard methods. Analysis for factor V Leiden mutation was carried out by PCR amplification followed by digestion with restriction enzyme Mnl I of PCR products, as previously reported (33) . Prothrombin variant 20210A was assessed as previously described (34) .
Plasminogen activity was assayed by a chromogenic substrate method using streptokinase as the activator (Berichrom PL, Behring, Scoppito, AQ, Italy) (35) . Plasminogen antigen was carried out by means of the electroimmunoassay (Laurell) (36) using 1 % agarose in a sodium barbital buffer (pH 8.6) containing 1.2% antiplasminogen antiserum supplied by Behringwerke (Marburg, Germany).
RESULTS
In all family members PT, aPTT, fibrinogen, antithrombin, protein C and protein S levels, and prothrombin genotype were normal. None of the family members presented with LA or APLA. The asymptomatic proposita (II-1 ) was heterozygous for plasminogen deficiency with 52% antigen and 54% activity levels ( Table  1 ). The older sister (II-2) of the proband was affected TABLE 1. Plasminogen activity (PLG:act) and antigen (PLG:Ag) APC sensitivity ratio (APC-SR) and DNA analysis for factor V Leiden mutation in the proposita and available family members * = symptomatic patients; GG = normal factor V; AG = heterozygous factor V Leiden.
with heterozygous plasminogen deficiency and was symptomatic. Another sister (II-3) of the proband showed a combined hypoplasminogenemia and APC resistance defect and was also symptomatic. The symptomatic father (I-1) of the proband had APC resistance.
The asymptomatic mother was probably affected by plasminogen deficiency.
Three of the five relatives of the paternal side were heterozygous for the factor V Leiden mutation (1-2, 1-4, II-4). However, only one (1-2) relative was symptomatic. Interestingly, one symptomatic patient (1-3) showed a normal fibrinolytic and coagulation pattern. Another relative (II-5) of the paternal side was normal and asymptomatic. Plasminogen and APC resistance data are summarized in Table 1 .
DISCUSSION
Congenital defects of plasminogen were first described in patients with thrombotic disorders (2, 3) . The inclusion of plasminogen defects among hereditary thrombophilic states is still a matter of discussion (10) (11) (12) (13) (14) . Available studies have not clearly associated plasminogen defects with an increased risk for VTE. In fact, affected patients are often asymptomatic and the preva-lence of plasminogen defects in thrombotic cohorts was similar to that observed in normal population (11) (12) (13) .
Factor V Leiden is a newly discovered thrombophilic condition characterized by the presence of APC resistance (15, 16) . It is highly represented in the Caucasian population and in patients with thrombotic disorders (17) (18) (19) (20) . Moreover, it has been detected with a variable frequency in severely symptomatic carriers of clotting inhibitors defects, suggesting that factor V Leiden may represent an additional risk factor predisposing to thrombosis (21-24).
Coinheritance of plasminogen deficiency and factor V Leiden defect recently has been reported in four unrelated kindreds who showed different clinical manifestations. No thrombotic event was observed among affected patients described by McColl et al. (27) . On the contrary, in the family reported by Züger et al. (28), two patients with the combined defect and only one with factor V Leiden suffered from thrombosis and/or pulmonary embolism. Finally, Castaman et al. (29) suggested that the association of APC resistance and plasminogen deficiency might not increase the risk for venous thrombosis as only two propositi with combined defects they observed were mildly symptomatic despite several haemostatic challenges. These observations suggest a limited role, if any, of plasminogen deficiency in determining thrombosis in carriers of factor V Leiden mutation. In the family we observed, there was a variable relation between thrombotic events and the presence or absence of clotting and fibrinolytic defects. Two of the four cases with isolated factor V Leiden mutation were symptomatic for VTE, whereas the patient with combined defect had only a superficial vein thrombosis, and one patient with hypoplasminogenemia suffered from recurrent abortions due to placental infarctions. Among unaffected family members one experienced a spontaneous DVT. In addition, the younger age of strate II patients might have influenced the development of thrombotic events because the period at risk was shorter.
The data available from the literature dealing with families with these combined defects are consistent with an increased risk of VTE in family members who were carriers of the factor V Leiden mutation ( Table 2 ). In In contrast, carriers of isolated plasminogen defect presented with a prevalence of VTE lower than that observed in unaffected family members. Interestingly, the prevalence of VTE in family members who were carriers of both defects was similar or even slightly lower than that found in carriers of isolated factor V Leiden mutation. These findings seem to be consistent with a limited role of plasminogen defect as an additional risk factor for VTE in carriers of factor V Leiden mutation. This conclusion is based on retrospective data, a small number of observations and possible referee biases and therefore should be verified.
Although only a few kindreds with combined plasminogen deficiency and factor V Leiden defect have been described, due to the high prevalence of factor V Leiden in the general population (1-15% depending on geographical area), it could be surmised that several other cases of combined defects will be discovered in the future. These additional observations are needed to clarify the clinical relevance of this association.
399.
21. van 
